Logo image
Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction
Journal article   Open access   Peer reviewed

Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction

Eugenia Lo, Jennifer Nguyen, Winny Oo, Elizabeth Hemming-Schroeder, Guofa Zhou, Zhaoqing Yang, Liwang Cui and Guiyun Yan
BMC infectious diseases, v 16(1), p154
16 Apr 2016
PMID: 27084511
url
https://doi.org/10.1186/s12879-016-1482-6View
Published, Version of Record (VoR) Open

Abstract

Antimalarials - pharmacology Antimalarials - therapeutic use Artemisinins - pharmacology China DNA, Protozoan - analysis DNA, Protozoan - metabolism Drug Resistance - genetics Genotype Humans Malaria, Falciparum - diagnosis Malaria, Falciparum - drug therapy Malaria, Vivax - drug therapy Malaria, Vivax - parasitology Microsatellite Repeats - genetics Myanmar Plasmodium falciparum - drug effects Plasmodium falciparum - genetics Plasmodium falciparum - isolation & purification Plasmodium vivax - drug effects Plasmodium vivax - genetics Plasmodium vivax - isolation & purification Protozoan Proteins - genetics Real-Time Polymerase Chain Reaction
Recent emergence of artemisinin-resistant P. falciparum has posed a serious hindrance to the elimination of malaria in the Greater Mekong Subregion. Parasite clearance time, a measure of change in peripheral parasitaemia in a sequence of samples taken after treatment, can be used to reflect the susceptibility of parasites or the efficiency of antimalarials. The association of genetic polymorphisms and artemisinin resistance has been documented. This study aims to examine clearance time of P. falciparum and P. vivax parasitemia as well as putative gene mutations associated with residual or recurred parasitemia in Myanmar. A total of 63 P. falciparum and 130 P. vivax samples collected from two internally-displaced populations and one surrounding village were examined for parasitemia changes. At least four samples were taken from each patient, at the first day of diagnosis up to 3 months following the initial treatment. The amount of parasite gene copy number was estimated using quantitative real-time PCR based on a species-specific region of the 18S rRNA gene. For samples that showed residual or recurred parasitemia after treatment, microsatellites were used to identify the 'post-treatment' parasite genotype and compared such with the 'pre-treatment' genotype. Mutations in genes pfcrt, pfmdr1, pfatp6, pfmrp1 and pfK13 that are potentially associated with ACT resistance were examined to identify if mutation is a factor for residual or persistent parasitemia. Over 30% of the P. falciprium infections showed delayed clearance of parasitemia after 2-3 days of treatment and 9.5% showed recurred parasitemia. Mutations in codon 876 of the pfmrp1 corroborated significance association with slow clearance time. However, no association was observed in the variation in pfmdr1 gene copy number as well as mutations of various codonsinpfatp6, pfcrt, and pfK13 with clearance time. For P. vivax, over 95% of the infections indicated cleared parasitemia at days 2-3 of treatment. Four samples were found to be re-infected with new parasite strains based on microsatellite genotypes after initial treatment. The appearance of P.falciparum infected samples showing delayed clearance or recurred parasitemia after treatment raises concerns on current treatment and ACT drug resistance.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Infectious Diseases
Logo image